Ilsung Pharm (003120) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.008x

Based on the latest financial reports, Ilsung Pharm (003120) has a cash flow conversion efficiency ratio of -0.008x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.10 Billion ≈ $-2.10 Million USD) by net assets (₩386.34 Billion ≈ $261.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ilsung Pharm defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Ilsung Pharm - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Ilsung Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Ilsung Pharm Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Ilsung Pharm ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Aditya Birla Money Limited NSE:BIRLAMONEY	0.060x
BCP Investment Corp. NASDAQ:BCIC	0.112x
KKB Engineering Berhad KLSE:9466	0.044x
Charoong Thai Wire and Cable Public Company Limited BK:CTW	-0.034x
Ersan Alisveris Hizmetleri & Gida Sanayi Ticaret AS IS:KIMMR	0.093x
Stars Microelectronics (Thailand) PCL BK:SMT	0.044x
BIOCELTIX S.A. ZY -10 F:XI3	-0.062x
CURATIS N AG SW:CURN	-0.024x

Annual Cash Flow Conversion Efficiency for Ilsung Pharm (2013–2025)

The table below shows the annual cash flow conversion efficiency of Ilsung Pharm from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Ilsung Pharm market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩386.34 Billion ≈ $261.82 Million	₩3.88 Billion ≈ $2.63 Million	0.010x	+190.91%
2024-12-31	₩385.13 Billion ≈ $261.00 Million	₩-4.26 Billion ≈ $-2.88 Million	-0.011x	+89.80%
2023-12-31	₩382.75 Billion ≈ $259.39 Million	₩-41.47 Billion ≈ $-28.11 Million	-0.108x	-23.91%
2022-12-31	₩445.57 Billion ≈ $301.95 Million	₩-38.97 Billion ≈ $-26.41 Million	-0.087x	-630.33%
2021-12-31	₩345.91 Billion ≈ $234.42 Million	₩5.70 Billion ≈ $3.87 Million	0.016x	+267.94%
2020-12-31	₩347.48 Billion ≈ $235.48 Million	₩1.56 Billion ≈ $1.06 Million	0.004x	-64.72%
2019-12-31	₩345.49 Billion ≈ $234.13 Million	₩4.39 Billion ≈ $2.97 Million	0.013x	-72.70%
2018-12-31	₩324.34 Billion ≈ $219.80 Million	₩15.09 Billion ≈ $10.23 Million	0.047x	+47.86%
2017-12-31	₩322.83 Billion ≈ $218.77 Million	₩10.16 Billion ≈ $6.88 Million	0.031x	+132.48%
2016-12-31	₩320.10 Billion ≈ $216.93 Million	₩-31.01 Billion ≈ $-21.02 Million	-0.097x	-610.55%
2015-12-31	₩318.34 Billion ≈ $215.74 Million	₩6.04 Billion ≈ $4.09 Million	0.019x	+48.84%
2014-12-31	₩328.68 Billion ≈ $222.74 Million	₩4.19 Billion ≈ $2.84 Million	0.013x	-18.74%
2013-12-31	₩322.74 Billion ≈ $218.72 Million	₩5.06 Billion ≈ $3.43 Million	0.016x	--

About Ilsung Pharm

KO:003120 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$89.79 Million

₩132.50 Billion KRW

Market Cap Rank

#19708 Global

#1008 in Korea

Share Price

₩19440.00

Change (1 day)

-1.32%

52-Week Range

₩18300.00 - ₩28650.00

All Time High

₩31693.76